Antibodies to Carbonic Anhydrase and IgG4 Levels in Idiopathic Chronic Pancreatitis: Relevance for Diagnosis of Autoimmune Pancreatitis
Overview
Authors
Affiliations
Background: Increased serum antibodies against carbonic anhydrase II (CA-II Ab) or IgG4 levels have been reported in cases of autoimmune chronic pancreatitis (ACP).
Aim: To assess the relevance of serum CA-II Ab and IgG4 levels for the diagnosis of ACP in idiopathic CP (ICP) versus alcoholic CP and Sjogren's syndrome (SS).
Subjects: This was a multicentre study involving 227 subjects divided into four groups: ICP (n = 54), normal controls (n = 54, paired by age and sex with ICP patients), alcoholic CP (n = 86), and SS (n = 33).
Methods: CA-II Ab was measured by ELISA and confirmed by western blotting. A score of easy clinical use with major clinical, morphological, and biochemical parameters for the diagnosis of ACP was applied.
Results: The percentage of patients with increased serum CA-II Ab was higher in the ICP group (28%) than in controls (1.9%) and in patients with alcoholic CP (10.5%), but lower than in patients with SS (64%). The proportion with elevated IgG4 levels was higher in the ICP group (15%) compared with controls (1.9%) and SS (0%) but not significantly different from alcoholic CP (8%). Most ICP patients (7/8) with high IgG4 levels exhibited increased CA-II Ab and a compatible ACP score. A definitive diagnosis of ACP by histological analysis was associated with other autoimmune disorders, an increase in both serum IgG4 and CA-II Ab levels, and IgG4 positive plasma cells.
Conclusions: The increase in serum IgG4 levels was strongly associated with elevated CA-II Ab levels, manifestations compatible with ACP, and lymphoplasmacytic infiltration when surgical specimens were available.
Update on Autoimmune Pancreatitis and IgG4-Related Disease.
Lanzillotta M, Vujasinovic M, Lohr J, Della Torre E United European Gastroenterol J. 2024; 13(1):107-115.
PMID: 39707927 PMC: 11866317. DOI: 10.1002/ueg2.12738.
Czarnywojtek A, Agaimy A, Pietronczyk K, Nixon I, Vander Poorten V, Makitie A Virchows Arch. 2024; 484(3):381-399.
PMID: 38316669 DOI: 10.1007/s00428-024-03757-0.
Tornel-Avelar A, Velarde Ruiz-Velasco J, Pelaez-Luna M World J Gastrointest Oncol. 2023; 15(6):925-942.
PMID: 37389107 PMC: 10302998. DOI: 10.4251/wjgo.v15.i6.925.
Uversky V, Redwan E, Makis W, Rubio-Casillas A Vaccines (Basel). 2023; 11(5).
PMID: 37243095 PMC: 10222767. DOI: 10.3390/vaccines11050991.
Wu H, Lei D, Zhang X, Wang M, Wang Y, Xia J Stem Cells Int. 2023; 2023:2742839.
PMID: 36818161 PMC: 9937754. DOI: 10.1155/2023/2742839.